Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gareth Morgan

Showing results (171-180 of 224) with videos related to

Pageof 23
Sort By:
Blood|September 3, 2015
Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging SystemRowan Kuiper, Mark van Duin, Martin H van Vliet, et al.
Blood Cancer Journal|November 25, 2018
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research ProjectSaad Z Usmani, Antje Hoering, Michele Cavo, et al.
Blood|November 25, 2003
Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCUBénédicte Neven, Isabelle Callebaut, Anne-Marie Prieur, et al.
Nature Communications|April 27, 2018
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expressionMina Ali, Ram Ajore, Anna-Karin Wihlborg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2020
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 TrialMeletios A Dimopoulos, Ivan Špička, Hang Quach, et al.
Plos One|November 16, 2016
Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased RiskPeter C Elwood, Gareth Morgan, Julieta Galante, et al.
Blood|July 26, 2014
The sialyltransferase ST3GAL6 influences homing and survival in multiple myelomaSiobhan V Glavey, Salomon Manier, Alessandro Natoni, et al.
The Oncologist|July 27, 2014
European perspective on multiple myeloma treatment strategies in 2014Heinz Ludwig, Pieter Sonneveld, Faith Davies, et al.
American Journal of Hematology|April 7, 2017
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition diseaseMeera Mohan, Amy Buros, Pankaj Mathur, et al.
Cancer Treatment Reviews|September 25, 2010
Treatment of relapsed and refractory multiple myeloma in the era of novel agentsNiels W C J van de Donk, Henk M Lokhorst, Meletios Dimopoulos, et al.
Pageof 23

Showing results (171-180 of 224) with videos related to

Sort By:
Pageof 23
Blood|September 3, 2015
Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging SystemRowan Kuiper, Mark van Duin, Martin H van Vliet, et al.
Blood Cancer Journal|November 25, 2018
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research ProjectSaad Z Usmani, Antje Hoering, Michele Cavo, et al.
Blood|November 25, 2003
Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCUBénédicte Neven, Isabelle Callebaut, Anne-Marie Prieur, et al.
Nature Communications|April 27, 2018
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expressionMina Ali, Ram Ajore, Anna-Karin Wihlborg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2020
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 TrialMeletios A Dimopoulos, Ivan Špička, Hang Quach, et al.
Plos One|November 16, 2016
Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased RiskPeter C Elwood, Gareth Morgan, Julieta Galante, et al.
Blood|July 26, 2014
The sialyltransferase ST3GAL6 influences homing and survival in multiple myelomaSiobhan V Glavey, Salomon Manier, Alessandro Natoni, et al.
The Oncologist|July 27, 2014
European perspective on multiple myeloma treatment strategies in 2014Heinz Ludwig, Pieter Sonneveld, Faith Davies, et al.
American Journal of Hematology|April 7, 2017
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition diseaseMeera Mohan, Amy Buros, Pankaj Mathur, et al.
Cancer Treatment Reviews|September 25, 2010
Treatment of relapsed and refractory multiple myeloma in the era of novel agentsNiels W C J van de Donk, Henk M Lokhorst, Meletios Dimopoulos, et al.
Pageof 23